If treatments for cognitive impairment are to be utilized successfully, clinicians must be able to determine whether they are effective and which patients should receive them.
In order to develop consensus on these issues, the International Society for CNS Clinical Trials and Methodology (ISCTM) held a meeting of experts on March 20, 2014, in Washington, DC. Consensus was reached on several important issues. Cognitive impairment and functional disability were viewed as equally important treatment targets.

Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, Davidson M, Lombardo I, Bowie CR, Buchanan RW, Bugarski-Kirola D,Carpenter WT, Csernansky JT, Dago PL, Durand DM, Frese FJ, Goff DCGold JM, Hooker CI, Kopelowicz A, Loebel A, McGurk SR, Opler LA, Pinkham AE, Stern RG.

Schizophr Bull. 2016 Jan;42(1):19-33. doi: 10.1093/schbul/sbv111. Epub 2015 Sep 11

Article-1